NASDAQ:EPIXESSA Pharma Stock Price, Forecast & News

$5.22

0.00 (0.00 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$5.10

Now: $5.22▼

$5.27

50-Day Range

$3.94

MA: $4.42▼

$5.25

52-Week Range

$1.41

Now: $5.22▼

$6.14

Volume9,414 shs

Average Volume24,082 shs

Market Capitalization$108.73 million

P/E RatioN/A

Dividend YieldN/A

Beta1.65

ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
ESSA Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.50, ESSA Pharma has a potential upside of 62.8% from its current price of $5.22.
Amount of Analyst Coverage
ESSA Pharma has only been the subject of 3 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
ESSA Pharma has received 327 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ESSA Pharma has received 212 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ESSA Pharma has received 60.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote “Outperform” if you believe EPIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EPIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ESSA Pharma does not currently pay a dividend.
Dividend Growth
ESSA Pharma does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ESSA Pharma insiders have not sold or bought any company stock.
Percentage Held by Institutions
68.68% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for ESSA Pharma are expected to grow in the coming year, from ($1.28) to ($1.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ESSA Pharma is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ESSA Pharma is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ESSA Pharma has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.63 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:EPIX

Previous Symbol

CUSIPN/A

CIK1633932

Webwww.essapharma.com

Phone778-331-0962

Debt

Debt-to-Equity RatioN/A

Current Ratio27.98

Quick Ratio27.98

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.93 per share

Price / Book2.70

Profitability

EPS (Most Recent Fiscal Year)($1.46)

Net Income$-10,440,000.00

Net MarginsN/A

Return on Equity-53.26%

Return on Assets-48.00%

Miscellaneous

Employees15

Outstanding Shares20,830,000

Market Cap$108.73 million

Next Earnings Date8/12/2020 (Estimated)

OptionableNot Optionable

Receive EPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.

ESSA Pharma (NASDAQ:EPIX) Frequently Asked Questions

How has ESSA Pharma's stock been impacted by COVID-19 (Coronavirus)?

ESSA Pharma's stock was trading at $4.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EPIX shares have increased by 28.3% and is now trading at $5.22. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ESSA Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ESSA Pharma.

When is ESSA Pharma's next earnings date?

ESSA Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for ESSA Pharma.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc (NASDAQ:EPIX) announced its earnings results on Thursday, May, 7th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.23. View ESSA Pharma's earnings history.

What price target have analysts set for EPIX?

3 analysts have issued 1 year target prices for ESSA Pharma's stock. Their forecasts range from $8.00 to $9.00. On average, they anticipate ESSA Pharma's share price to reach $8.50 in the next year. This suggests a possible upside of 62.8% from the stock's current price. View analysts' price targets for ESSA Pharma.

Has ESSA Pharma been receiving favorable news coverage?

News coverage about EPIX stock has been trending very negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ESSA Pharma earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutESSA Pharma.

Are investors shorting ESSA Pharma?

ESSA Pharma saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 26,800 shares, a decrease of 6.0% from the April 30th total of 28,500 shares. Based on an average trading volume of 32,800 shares, the short-interest ratio is presently 0.8 days. Approximately 0.2% of the shares of the company are sold short. View ESSA Pharma's Current Options Chain.

Who are some of ESSA Pharma's key competitors?

Some companies that are related to ESSA Pharma include Mirum Pharmaceuticals (MIRM), Prothena (PRTA), Calithera Biosciences (CALA), CytomX Therapeutics (CTMX), XBiotech (XBIT), Avedro (AVDR), Puma Biotechnology (PBYI), Albireo Pharma (ALBO), Seres Therapeutics (MCRB), Merus (MRUS), Aeglea Bio Therapeutics (AGLE), Axovant Sciences (AXON), MEI Pharma (MEIP), ANI Pharmaceuticals (ANIP) and Ocular Therapeutix (OCUL). View all competitors.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include Aurinia Pharmaceuticals (AUPH), REDHILL BIOPHAR/S (RDHL), Trevena (TRVN), Corbus Pharmaceuticals (CRBP), Lipocine (LPCN), Protalix Biotherapeutics (PLX), AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Biopharmx (BPMX) and Heat Biologics (HTBX).

Who are ESSA Pharma's key executives?

ESSA Pharma's management team includes the following people:

Dr. David Ross Parkinson, Pres, CEO & Director (Age 69)
Mr. David S. Wood, Chief Financial Officer (Age 62)
Mr. Peter A. Virsik, Exec. VP & COO (Age 48)
Dr. Raymond Andersen, CTO, Sec. & Director (Age 72)
Dr. Marianne D. Sadar, Chief Scientific Officer & Director (Age 58)

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Soleus Capital Management L.P. (10.02%), RA Capital Management L.P. (4.62%), Janus Henderson Group PLC (0.96%) and Advisor Group Holdings Inc. (0.04%).

Which institutional investors are selling ESSA Pharma stock?

EPIX stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P..

Which institutional investors are buying ESSA Pharma stock?

EPIX stock was bought by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., Janus Henderson Group PLC, and Advisor Group Holdings Inc..

How do I buy shares of ESSA Pharma?

Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ESSA Pharma's stock price today?

One share of EPIX stock can currently be purchased for approximately $5.22.

How big of a company is ESSA Pharma?

ESSA Pharma has a market capitalization of $108.73 million. The company earns $-10,440,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. ESSA Pharma employs 15 workers across the globe.

What is ESSA Pharma's official website?

The official website for ESSA Pharma is www.essapharma.com.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 778-331-0962 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff